Current Report Filing (8-k)
March 02 2018 - 4:08PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): March 1, 2018
NeuroOne
Medical Technologies Corporation
(Exact
name of registrant as specified in its charter)
000-54716
|
|
20-0863354
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
10006
Liatris Lane, Eden Prairie, MN 55347
(Address
of principal executive offices and zip code)
952-237-7412
(Registrant’s
telephone number including area code)
(Registrant’s
former name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
Growth Company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 1.01. Entry
into a Material Definitive Agreement.
On
March 1, 2018, Wade Fredrickson, a greater than 5% stockholder of NeuroOne Medical Technologies Corporation (the “
Company
”)
entered into a lock-up agreement (the “
Agreement
”) with the Company in which he agreed, subject to certain
exceptions, not to offer, sell, transfer or otherwise dispose of the Company’s securities for a period of 18 months following
the effective date of the Agreement.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
NEUROONE
MEDICAL TECHNOLOGIES CORPORATION
|
|
|
|
|
By:
|
/s/
Dave Rosa
|
|
|
Name:
David Rosa
|
|
|
Title: Chief
Executive Officer
|
Dated:
March 2, 2018
2